Given the silent nature and prevalence of FH, current guidelines support the testing of genes encoding the low-density lipoprotein receptor (LDLR), apolipoprotein B (APOB), and proprotein convertase subtilisin/kexin 9 (PCSK9) in patients that comply with clinical diagnostic criteria, and cascade screening of their family members9. This evidence concerns the gene LDLR and familial hyperaldosteronism.